The first place... the last word.
TrustTheEvidence.net
Discover the truth behind the research findings that affect everyday healthcare.
HONcode Certified
This site complies with the HONcode standard for trustworthy health information: verify here.
Bloggers
Carl Heneghan
Deputy Director of the CEBM, GP and clinical lecturer at the University of Oxford.
Ami Banerjee
Cardiology trainee and clinical research fellow at the University of Oxford
Tags
Carl Heneghan in action
See Carl Heneghan in action in the CEBM's workshop videos.
Click here
Navigator
Twitter TrustTheEvidence.net
Search the TRIP Database
Links
- Carl Heneghan interviewed by Channel 4: why flu jabs for elderly may be ineffective
- BMJ podcast interview with Carl Heneghan & Matthew Thompson about the media response to their paper on the prescription of antivirals to children
- ITN report: Swine flu drug 'harmful to children'
- Trust The Evidence on feedburner
- Trust The Evidence on MedPedia
- Trust The Evidence on friendfeed
Recent blog posts
- Stenting versus surgery-lessons from the heart to the brain
- Research into physical education activity in children: please sir can I have some more?
- Flu vaccines in the elderly-40 years of expensive policy with no evidence?
- How good are we at diagnosing serious infection in children?
- Why everyone should know about solar disinfection
- Another anti-obesity pill bites the dust
- Reflections on Haiti. Natural disasters, conflict, or disease-which is the biggest threat?
- 2010: call for reduced bias in clinical studies
- Trimming the fat- complicated devices will not solve a simple problem
- Association and causation: the link between childhood IQ and mortality
Top Ten Blog Articles
- Heart age calculator should come with a warning
- Understanding evidence-based medicine in 4 days. Lesson 1: Clinical significance is all about risk
- Steroids good in sore throat, Tamiflu not that good in swine flu
- Is organic food a waste of money?
- US Healthcare debate 2009. Should passion and anecdote ever outweigh evidence?
- Statins - are they worth it?
- Aspirin for all? No
- Why is Obama talking up Evidence-Based Medicine?
- Can the death of an icon impact our health?
- Do you know the right age to start cervical cancer screening?
Blog Archive
- February 2009 (5)
- March 2009 (5)
- April 2009 (4)
- May 2009 (4)
- June 2009 (6)
- July 2009 (6)
- August 2009 (5)
- September 2009 (4)
- October 2009 (6)
- November 2009 (8)
- December 2009 (5)
- January 2010 (4)
- February 2010 (3)
- March 2010 (2)
rosiglitazone
15th June 2009 09:55am
Some drugs just never go away, but they should
We first criticized this drug in 2006, when in the BMJ we first mooted rosiglitazone in the DREAM trial – which cost $23million - caused a significant increase in heart failure, despite the population being at low risk of such a problem. The drug showed no clear benefit at 3 years on clinical outcomes and the rate of all cardiovascular events tended to be higher in the treatment group.
Recent comments
3 weeks 13 hours ago
6 weeks 1 day ago
6 weeks 1 day ago
6 weeks 1 day ago
6 weeks 4 days ago
6 weeks 6 days ago
7 weeks 2 days ago
7 weeks 2 days ago
8 weeks 6 days ago
8 weeks 6 days ago